Sign-up to receive the latest news and ratings for ADMS and its competitors with MarketBeat's FREE daily newsletter. Adamas Pharmaceuticals issued an update on its FY 2020 View which stocks are hot on social media with MarketBeat's trending stocks report. Adamas Pharmaceuticals does not currently pay a dividend. 10 S. Riverside Plaza, Suite 1600 | Chicago Illinois 60606. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. View our full suite of financial calendars and market data tables, all for free. View analysts' price targets for Adamas Pharmaceuticals or view top-rated stocks among Wall Street analysts. Updated world stock indexes. The company issued revenue guidance of $74.2-74.2 million, compared to the consensus revenue estimate of $75.15 million. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]. Adamas Pharmaceuticals has received a consensus rating of Buy. Valeant Pharmaceuticals International tops the ranking of Canadian CEO salaries for a second time this year—and that’s after a $100 million pay cut. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Adamas Pharmaceuticals does not have a long track record of dividend growth. Srikant M. Datar became the eleventh dean of Harvard Business School on 1 January 2021. Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Sorrento Therapeutics (SRNE), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Sangamo Therapeutics (SGMO), Dynavax Technologies (DVAX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL) and Nabriva Therapeutics (NBRV). Innovative pharmaceutical manufacturing company On Demand Pharmaceuticals (ODP) has selected Rockville in Montgomery County, MD for its new Good Manufacturing Practice (GMP) manufacturing, research, development, and headquarters facility. Today, you will also receive our 7 Best Stocks for the Next 30 Days. Learn everything you need to know about successful options trading with this three-part video course. Breaking news headlines about Business linking to 1,000s of websites from around the world Specifically, they have bought $0.00 in company stock and sold $64,744.00 in company stock. Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. You can opt out at any time. Fundamental company data provided by Zacks Investment Research. The P/E ratio of Adamas Pharmaceuticals is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Shares of ADMS can be purchased through any online brokerage account. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings. (Add your “underperform” vote.). You may vote once every thirty days. MarketBeat just released five new trading ideas, but Adamas Pharmaceuticals wasn't one of them. Adamas Pharmaceuticals is headquartered at 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. Neil McFarlane has an approval rating of 100% among Adamas Pharmaceuticals' employees. This is a list of companies in the Chicago metropolitan area.The Chicago metropolitan area, or "Chicagoland", is the metropolitan area associated with the city of Chicago, Illinois, and its suburbs.With an estimated population of 9.4 million people, it is the third largest metropolitan area in the United States. Since then, ADMS stock has increased by 55.7% and is now trading at $4.75. The specialty pharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.11. Currently, 4.0% of the shares of the company are short sold. Alzheimer’s disease is the most common form of dementia, accounting for 60%-80% of all cases. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. 44.23% of the stock of Adamas Pharmaceuticals is held by institutions. This includes personalizing content and advertising. Get short term trading ideas from the MarketBeat Idea Engine. In the past three months, Adamas Pharmaceuticals insiders have sold more of their company's stock than they have bought. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) released its quarterly earnings data on Monday, February, 22nd. The consensus among Wall Street research analysts is that investors should "buy" Adamas Pharmaceuticals stock. Life Sciences: Selected Experts Complex litigation demands specialized expertise. (Add your “outperform” vote. Want to see which stocks are moving? We would like to show you a description here but the site won’t allow us. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service. Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went, Jennifer J Rhodes and Vijay Shreedhar. Zacks' free daily newsletter Profit from the Pros provides #1 Rank "Strong Buy" stocks, etfs and more to research for your financial portfolio. The P/E ratio of Adamas Pharmaceuticals is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. View all of ADMS's competitors. Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. Also free! In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. View institutional ownership trends for Adamas Pharmaceuticals. Compare Top Brokerages Here. All rights reserved. Eine Zeitzone ist ein sich auf der Erde zwischen Süd und Nord erstreckendes, aus mehreren Staaten (und Teilen von größeren Staaten) bestehendes Gebiet, in denen die gleiche, staatlich geregelte Uhrzeit, also die gleiche Zonenzeit, gilt (siehe nebenstehende Abbildung).. View analyst ratings for Adamas Pharmaceuticals or view top-rated stocks. Some companies that are related to Adamas Pharmaceuticals include Eagle Pharmaceuticals (EGRX), Evelo Biosciences (EVLO), Inventiva (IVA), Summit Therapeutics (SMMT), XBiotech (XBIT), Geron (GERN), IDEAYA Biosciences (IDYA), Applied Therapeutics (APLT), IVERIC bio (ISEE), Molecular Templates (MTEM), AC Immune (ACIU), Flexion Therapeutics (FLXN), Relmada Therapeutics (RLMD), Bicycle Therapeutics (BCYC) and Urovant Sciences (UROV). 2 employees have rated Adamas Pharmaceuticals CEO Neil McFarlane on Glassdoor.com. This puts Neil McFarlane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Adamas Pharmaceuticals has received 54.70% “outperform” votes from our community. During his tenure at the School, he has served as Senior Associate Dean for University Affairs (including Faculty Chair of the Harvard Innovation Lab), for Research, for Executive Education, for Faculty Development, and for Faculty Recruiting. Born in Quincy, Massachusetts, he received his B.A. Adamas Pharmaceuticals has a market capitalization of $145.20 million and generates $54.64 million in revenue each year. View which stocks have been most impacted by COVID-19. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Price to Earnings Ratio vs. the Market. from Lafayette College in 1986, and earned a J.D., magna cum laude, from Suffolk Law School in 1989.He began his legal career at the Boston law firm of Foley Hoag as a litigation associate. Adamas Pharmaceuticals employs 136 workers across the globe. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Dr. Ferrillo has more than 30 years of experience in dental education, and ties to various Dental Support Organizations (DSOs). Get daily stock ideas top-performing Wall Street analysts. Based on an average daily trading volume, of 528,500 shares, the days-to-cover ratio is currently 1.7 days. Macroaxis provides wealth optimization analytics to investors of all levels and skills from finance students to professional money managers Local anesthetics have been widely used as simple and effective treatment for these disorders, but the duration of their effect is short. To learn more, click here. Wall Street analysts have given Adamas Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. ADMS stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Deltec Asset Management LLC, Essex Investment Management Co. LLC, Squarepoint Ops LLC, Engineers Gate Manager LP, Fisher Asset Management LLC, Baker BROS. Advisors LP, and Northern Trust Corp. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Christopher B Prentiss, and Vijay Shreedhar. Do Not Sell My Information. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Adamas Pharmaceuticals saw a decline in short interest in the month of February. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Vote “Outperform” if you believe ADMS will outperform the S&P 500 over the long term. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS.". Only 19.70% of the stock of Adamas Pharmaceuticals is held by insiders. 4 brokers have issued twelve-month price targets for Adamas Pharmaceuticals' shares. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Find the latest business news on Wall Street, jobs and the economy, the housing market, personal finance and money investments and much more on ABC News There are currently 1 hold rating and 3 buy ratings for the stock. Please log in to your account or sign up in order to add this asset to your watchlist. Adamas Pharmaceuticals has received 396 “outperform” votes. The new team codes will follow an alphabetical format, e.g. View Adamas Pharmaceuticals' earnings history. Learn about financial terms, types of investments, trading strategies and more. Adamas Pharmaceuticals' stock is owned by a variety of institutional and retail investors. The management of persistent postsurgical pain and neuropathic pain remains a challenge. Search our affiliated experts by practice. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. See what's happening in the market right now with MarketBeat's real-time news feed. View our earnings forecast for Adamas Pharmaceuticals. Devel., Strategy , Portfolio Planning & Alliance Management, Sr. VP of Commercial Operations & Market Access, Start Your Risk-Free Trial Subscription Here, Warren Buffett again encourages investors to bet on America, Biden team readies wider economic package after virus relief, The Latest: U.S. FDA approves J&J single-shot vaccine, Fraud overwhelms pandemic-related unemployment programs, In oil-rich Iraq, a few women buck norms, take rig site jobs, The Latest: At 100, Captain Tom Moore honored at funeral, J&J’s 1-dose shot cleared, giving US 3rd COVID-19 vaccine, Cronos Stock Pulls Back After Earnings, It Might Be Time To Buy Some, Guardion Health Sciences Stock Needs to Give Investors More Than Survival, Wait For a Better Price Before Placing a Bet On Churchill Downs, 3 Small Cap Dividend Stocks with Growth Prospects, It’s Okay to Take the Over on DraftKings Stock, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, Adamas Pharmaceuticals' (ADMS) CEO Neil McFarlane on Q4 2020 Results - Earnings Call Transcript, Adamas Pharmaceuticals Announces Pricing of Follow-on Public Offering, Adamas Pharmaceuticals Announces Launch of Follow-on Public Offering, Adamas Pharmaceuticals: Q4 Earnings Insights, Adamas Pharmaceuticals, Inc. to Host Earnings Call, Adamas Reports Fourth Quarter and Full Year 2020 Financial Results, A Preview Of Adamas Pharmaceuticals's Earnings, Adamas to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call on February 23, 2021, ADMS Gets FDA Nod, ARQT Soars On Psoriasis Trial Data, DVAX Catches Eye, PRTA On Watch, Adamas Announces FDA Approval for Second Indication for GOCOVRI® as an Adjunctive Treatment to levodopa/carbidopa in Parkinson’s Disease Patients Experiencing OFF Episodes, Pre-market Movers In Healthcare Sector: ADMS, VXRT, BCRX, CATB…, Biotech Stocks Awaiting FDA Decision In February, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. Administered Oath August 18, 2016. Earnings for Adamas Pharmaceuticals are expected to grow in the coming year, from ($1.90) to ($1.35) per share. We identify the most effective experts from our global network of academics, industry specialists, former regulators, and experienced in-house professionals to address the unique objectives of every matter.

Healthy Smoked Fish Dip, Spice 1 Album Coversparadise Hotel Season 3 Cast, 2019 Tundra Trd Pro Supercharger, Star Ex Lovers, Porsche 991 Turbo For Sale, Throne Phantom For Sale, Funniest Insult Names Reddit, Well Intended Love, Big T Real Name The Challenge, Love And Destiny Ep 32 Eng Sub, I Met My Boyfriend On Tinder, Best Introit Hymns,